KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Research & Development (2016 - 2025)

Supernus Pharmaceuticals has reported Research & Development over the past 15 years, most recently at $27.8 million for Q4 2025.

  • Quarterly Research & Development fell 2.86% to $27.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.2 million through Dec 2025, down 2.35% year-over-year, with the annual reading at $106.2 million for FY2025, 2.35% down from the prior year.
  • Research & Development was $27.8 million for Q4 2025 at Supernus Pharmaceuticals, down from $29.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $29.4 million in Q3 2025 and troughed at $15.0 million in Q1 2021.
  • The 5-year median for Research & Development is $22.4 million (2023), against an average of $22.6 million.
  • Year-over-year, Research & Development plummeted 30.53% in 2021 and then soared 48.79% in 2023.
  • A 5-year view of Research & Development shows it stood at $21.1 million in 2021, then dropped by 15.68% to $17.8 million in 2022, then skyrocketed by 31.35% to $23.3 million in 2023, then grew by 22.7% to $28.6 million in 2024, then decreased by 2.86% to $27.8 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Research & Development are $27.8 million (Q4 2025), $29.4 million (Q3 2025), and $22.1 million (Q2 2025).